Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Transplantation|May 11, 2011
Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrheaDamien Roos-Weil, Katia Ambert-Balay, Fanny Lanternier, et al.
Hemasphere|July 31, 2024
Impact of second autologous stem-cell transplantation at relapsed multiple myeloma: A French multicentric real-life studyAxel André, Lydia Montes, Damien Roos-Weil, et al.
Leukemia|December 6, 2023
ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemiaMariana Tannoury, Marianne Ayoub, Léa Dehgane, et al.
Blood|May 28, 2020
Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell featuresDamien Roos-Weil, Brian Giacopelli, Marine Armand, et al.
Seminars in Hematology|May 25, 2025
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom's MacroglobulinemiaShayna Sarosiek, Anne-Marie L Becking, Andrew Branagan, et al.
British Journal of Haematology|March 21, 2023
Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell-free DNA improves diagnosis of primary CNS lymphomaClotilde Bravetti, Michaël Degaud, Marine Armand, et al.
Annals of Hematology|November 5, 2024
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemiaCécile Tomowiak, Stéphanie Poulain, Morgane Nudel, et al.
Blood Advances|March 28, 2018
B-cell tumor development in Tet2-deficient miceEnguerran Mouly, Hussein Ghamlouch, Veronique Della-Valle, et al.
British Journal of Haematology|April 24, 2024
Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study)Florence Nguyen-Khac, Marine Baron, Romain Guièze, et al.
Blood|June 28, 2019
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group studyAnne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, et al.
Pageof 10